212 related articles for article (PubMed ID: 31025554)
1. Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Sun T; Zhao Q; Zhang C; Cao L; Song M; Maimela NR; Liu S; Wang J; Gao Q; Qin G; Wang L; Zhang Y
Cancer Med; 2019 Jun; 8(6):3059-3071. PubMed ID: 31025554
[TBL] [Abstract][Full Text] [Related]
2. Differentially Expressed Gene Screening, Biological Function Enrichment, and Correlation with Prognosis in Non-Small Cell Lung Cancer.
Huang H; Huang Q; Tang T; Zhou X; Gu L; Lu X; Liu F
Med Sci Monit; 2019 Jun; 25():4333-4341. PubMed ID: 31181055
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.
Huang H; Li T; Chen M; Liu F; Wu H; Wang J; Chen J; Li X
Cell Mol Biol Lett; 2018; 23():54. PubMed ID: 30505321
[TBL] [Abstract][Full Text] [Related]
4. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
Liu X; Liu X; Li J; Ren F
Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
6. Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.
Piao J; Sun J; Yang Y; Jin T; Chen L; Lin Z
Gene; 2018 Mar; 647():306-311. PubMed ID: 29305979
[TBL] [Abstract][Full Text] [Related]
7. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of key genes associated with non-small-cell lung cancer.
Ma Q; Xu Y; Liao H; Cai Y; Xu L; Xiao D; Liu C; Pu W; Zhong X; Guo X
J Cell Physiol; 2019 Dec; 234(12):22742-22752. PubMed ID: 31127628
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis.
Zhou W; Yin M; Cui H; Wang N; Zhao LL; Yuan LZ; Yang XP; Ding XM; Men FZ; Ma X; Na JR
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3375-84. PubMed ID: 26439031
[TBL] [Abstract][Full Text] [Related]
10. Identification of miRNAs and differentially expressed genes in early phase non-small cell lung cancer.
Tian W; Liu J; Pei B; Wang X; Guo Y; Yuan L
Oncol Rep; 2016 Apr; 35(4):2171-6. PubMed ID: 26781349
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
13. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
[TBL] [Abstract][Full Text] [Related]
14. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
15. Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes.
Zhou D; Xie M; He B; Gao Y; Yu Q; He B; Chen Q
Mol Med Rep; 2017 Oct; 16(4):5129-5136. PubMed ID: 28849055
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer.
Sheikhshabani SH; Modarres P; Ghafouri-Fard S; Amini-Farsani Z; Khodaee L; Shaygan N; Amini-Farsani Z; Omrani MD
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1970. PubMed ID: 38351531
[TBL] [Abstract][Full Text] [Related]
17. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
18. Analysis of gene expression profiles of non-small cell lung cancer at different stages reveals significantly altered biological functions and candidate genes.
Wang J; Song J; Gao Z; Huo X; Zhang Y; Wang W; Qi J; Zheng S
Oncol Rep; 2017 Mar; 37(3):1736-1746. PubMed ID: 28098899
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis.
Sun T; Zhang P; Zhang Q; Wang B; Zhao Q; Liu F; Ma X; Zhao C; Zhou X; Chen R; Ouyang S
Heliyon; 2024 May; 10(10):e30780. PubMed ID: 38765024
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells.
Fang Y; Zhang C; Wu T; Wang Q; Liu J; Dai P
PLoS One; 2017; 12(1):e0170609. PubMed ID: 28114404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
